Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 5/20 | 0.40 |
| ▸ | MMP3 | P08254 | 5/20 | 0.40 |
| ▸ | MMP1 | P03956 | 3/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | Q9HBH1 | 1/20 | 0.40 | |
| ▸ | BMP1 | P13497 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609165 | 0.84 | TSHR (0.54) | BIRC2USP2TSHRALDH1A1MMP2 | |
| SCHEMBL21994104 | 0.82 | MME (0.67) | MMELTA4HALDH1A1MMP2MMP3 | |
| SCHEMBL25654468 | 0.78 | MMP2 (0.45) | USP2TSHRMMP2MMP3MMP1 | |
| SCHEMBL13768731 | 0.77 | MME (0.45) | MMEBIRC2MMP2MMP3MMP1 | |
| SCHEMBL18239031 | 0.77 | MME (0.45) | MMEBIRC2MMP2MMP3MMP1 | |
| SCHEMBL16279524 | 0.77 | CA2 (0.57) | MMEUSP2TSHRALDH1A1MMP2 | |
| SCHEMBL26992372 | 0.77 | HDAC8 (0.50) | USP2TSHR | |
| SCHEMBL17321831 | 0.77 | BIRC2 (0.45) | MMEBIRC2USP2TSHRALDH1A1 | |
| SCHEMBL29400840 | 0.76 | NAALAD2 (0.46) | MMEBIRC2USP2TSHRALDH1A1 | |
| SCHEMBL9911498 | 0.76 | MME (0.38) | MMELTA4HTSHRALDH1A1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-14 | — | — | US | disclosed |
| US-11725024-B2 | Antibody drug conjugates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399356-A1 | ANTIBODY DRUG CONJUGATES | STING1, CGAS, TBK1 | MME 3685/4885LTA4H 1291/4885BIRC2 1035/4885 |
| US-11725024-B2 | Antibody drug conjugates | STING1, CGAS, TBK1 | MME 3685/4885LTA4H 1291/4885BIRC2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.